Cardiovascular pharmacology core reviews: aspirin

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Trials

Background:

• Acetylsalicylic acid (aspirin) is extensively studied, yet optimal dosing and primary prevention of atherothrombotic events are controversial.
• Understanding aspirin's effects on the cyclooxygenase pathway is crucial for its clinical application.

Purpose of the Study:

• To review the evidence on aspirin's role in primary and secondary prevention of atherothrombotic events.
• To analyze aspirin dosing strategies, drug interactions (e.g., with ticagrelor), and aspirin resistance.
• To provide a perspective on evidence-based aspirin use in clinical practice, referencing major guidelines.

Main Methods:

• Review of clinical trials investigating aspirin for primary and secondary prevention.
• Analysis of prospective and retrospective studies on aspirin dosage.
• Examination of literature on aspirin's interaction with ticagrelor and the phenomenon of aspirin resistance.
• Synthesis of current major society guidelines on aspirin use.

Main Results:

• The article synthesizes existing data on aspirin's efficacy and safety in preventing atherothrombotic events.
• It highlights ongoing debates regarding optimal aspirin dosage and its application in primary prevention.
• Potential interactions and the concept of aspirin resistance are discussed in the context of clinical outcomes.

Conclusions:

• Evidence-based use of aspirin requires careful consideration of individual patient factors, optimal dosing, and potential interactions.
• Major society guidelines offer frameworks for aspirin prescription, but clinical judgment remains essential.
• Further research may clarify optimal strategies for aspirin in atherothrombotic event prevention.